• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Mankind Pharma falls after Q3 PAT drops 16% YoY to Rs 380 crore

Raja Aditya by Raja Aditya
2 years ago
in Pharmaceutical & Chemical, Science News
0
Q3

Mankind Pharma falls after Q3 PAT drops 16% YoY to Rs 380 crore | Neo Science Hub

Mankind Pharmaceutical down 2.76 percent to Rs 2,560.05 following a 16.2% drop in the company’s consolidated net profit to Rs 380.23 crore in Q3 FY25 compared to Rs 453.76 crore in Q3 FY24.

In the third quarter of FY25, however, income from operations climbed 23.9% year over year (YoY) to Rs 3,230 crore.

In Q3 of FY25, profit before tax was Rs 497.33 crore, representing an 11.56% decrease from the Rs 562.32 crore achieved in Q3 of FY24.

In the December 2024 quarter, EBITDA increased 36.4% year over year to Rs 833 crore. In Q3 of FY25, the EBITDA margin increased to 25.8% from 23.4% in the same quarter the year before.

In the third quarter of FY25, foreign revenue increased by 120.8% YoY to Rs 457 crore, while domestic revenue increased by 15.5% YoY to Rs 2,773 crore.

A rise in base business, bolstered by new launches over the past 12 months and BSV consolidation, drove export growth. The company launched one new product in the US during the quarter, bringing the total number of items launched to 42.

With consistent growth across all major brands, the company’s consumer healthcare division reported a 30% increase in revenue to Rs 193 crore in Q3 FY25. Manforce Condom, Gas-o-fast, and HealthOk saw strong growth in secondary sales of 13%, 28%, and 26% YoY, respectively, and gained significant traction with recent strategic launches, such as Manforce Epic (Premium category), Nimulid (Pain Management), etc.

In FY25’s third quarter, cash flow from operations was Rs 460 crore.

“In Q3 FY25, we delivered a healthy revenue growth of 24% YoY with a great adjusted EBITDA margin of 27.7%, led by ongoing outperformance in chronic, significant recovery in OTC, and consolidation of BSV,” stated Rajeev Juneja, vice chairman and managing director of Mankind Pharma. OTC’s 30% YoY sales increase was bolstered by previous year’s strategic efforts.

With an emphasis on protecting branding, increasing productivity, and implementing best practices to guarantee long-term sustainable growth, the integration of BSV is proceeding as planned. 2024 has been a year of transformation; BSV now has a high-entry barrier super specialty portfolio, a fast-growing specialty chronic section, a consistent base business, and a high potential over-the-counter company.

-NSH Digidesk

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: EBITDAfeaturedMankind PharmaQ3 PAT drops 16%Rs 380 croresciencenews
Raja Aditya

Raja Aditya

Associate Editor for Neo Science Hub Magazine

Other Posts

Young maize in paired rows on raised beds with water in the furrows between them

Lifting the Crop Off the Floor: Why Raised Beds Are Gaining Ground in a Water-Short Country

November 15, 2026
1
Trays of green and purple microgreens beside a field being sprayed

Small Leaves, Small Particles: Microgreens Have the Evidence. Nano-Urea Is Still Earning It

November 15, 2026
3

A Crore and a Half Recharge Pits Later: What India’s Water Reforms Can, and Cannot, Teach the Global South

A Purple Broccoli That Seeds in Delhi and a Sponge Gourd That Shrugs Off a Virus

Fourteen Seconds to 241 km/h and Back: What a Runway Test Says About Where Car Performance Now Lives

An Aeroplane on a Helipad: What Electra’s Manhattan Landing Proves, and What It Does Not

After the Space Station: NASA Opens the Contest to Become a Tenant in Orbit

At 94, the Air Force Counts Its Squadrons, and Waits for an Engine India Can Call Its Own

Next Post
Brain

Study found out that Pregnancy reshapes Mother's Brain, lowers Gray Matter with partial recovery Postpartum

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
7

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist